Summary
Introduction
It is well established that loss of bone starts at the time of the menopause, that it is associated with an elevation of the fasting plasma and urinary calcium and urinary hydroxyproline (Gallagher & Nordin, 1973) and that it can be attributed in part at least to an increase in bone resorption. Many variables have been used to monitor the onset and progression of postmenopausal bone loss, but little if any attention appears to have been paid to the plasma alkaline phosphatase in this connection. We have recently noticed that the plasma alkaline phosphatase tends to fall on oestrogen therapy and we have, therefore, examined our data to establish whether the alkaline phosphatase activity rises at the menopause. We now record that this is in fact the case. 
I Methods
We report plasma alkaline phosphatase activities in 27 pairs of pre-and post-menopausal women matched for age. All patients were referred to our Menopause Clinic, the postmenopausal patients because of typical menopausal complaints and the premenopausal patients because of symptoms thought to be related to the menstrual cycle. Most of the latter suffered from premenstrual tension and all were menstruating regularly. Patients with clear hormonal abnormalities were excluded, as were patients with known incidental disease. All samples were collected in the fasting state. The data presented are the means of two observations on untreated cases.
The method of Kind & King (1954) was used to determine the plasma alkaline phosphatase activities.
Urine samples were obtained from every patient at the same time as the blood sample and analysed for hydroxyproline and creatiniine by standard Auto-Analyzer methods (Hodgkison & Knowles, 1976) . The results presented are the hydroxyproline/creatinine ratios (in molar units) and are also the means of two separate observations. The serum glutamic-oxaloacetic transaminase activity and bilirubin concentration were measured in the same plasma samples by Auto-Analyzer methods.
Results
The mean plasma alkalie phosphatase in the premenopausal women was 526 2.1 (SE) and 8.1 & 2.3 King Armstrong units in the postmenopausal women. This difference was significant pausal women was 0.009 f 0.0027 and in thepostmenopausal women 0.0146 0.0047. This dfference was highly significant (P < 0.001) (see Fig.   1 ). A small but non-significant rise in the serum glutamic-oxaloacetic transaminase activity was noted (15.4 i d 1 in the premenopausal and 17.6 i.u./l in the postmenopausal) but there was no difference in bilirubin concentrations (1 1.7 and 10.6 pmol/l respectively). The normal ranges are 8-22 i.u./l for serum glutamic-xaloacetic transaminase and 3-15 pmol/l for bilirubin.
Discussion
Since the two groups of subjects were matched for age, age as such cannot explain the rise in alkaline phosphatase we have observed. It is therefore liely to be a menopausal effect and is compatible with the observation, which we will be reporting elsewhere, that plasma alkaline phosphatase activity falls on oestrogen therapy. The fact that it is associated with a rise in urinary hydroxyproline strongly suggests that it is the bone phosphatase activity which rises at the menopause, and it is possible that the actual level ( l i e that of the urinary hydroxyproline/creatinine ratio) reflects the rate of bone loss. This possibility is presently under examination. It seems unlikely that the observation we report here is attributable to altered liver function but this possibility cannot be entirely excluded.
